NEW DELHI, Yuni 22 (Xinhua) - Kamfanin samar da allurar rigakafi na Indiya Bharat Biotech's Covaxin ya nuna ingancin kashi 77.8 cikin 100 na gwaji na kashi na uku, in ji kafofin watsa labarai da yawa a ranar Talata.
Wani rahoto ya ce "Bharat Biotech's Covaxin yana da kashi 77.8 cikin 100 na tasiri wajen kariya daga COVID-19, bisa ga bayanai daga gwaji na III da aka gudanar akan mahalarta 25,800 a duk faɗin Indiya," in ji wani rahoto.
Adadin ingancin ya fito ne a ranar Talata bayan kwamitin ƙwararrun batutuwa (SEC) na Babban Mai Kula da Magunguna na Indiya (DCGI) ya gana tare da tattauna sakamakon.
Kamfanin harhada magunguna ya gabatar da bayanan gwaji na kashi III na maganin ga DCGI a karshen mako.
Rahotanni sun ce ana sa ran kamfanin zai gudanar da taron "gabatarwa" tare da hukumomin Hukumar Lafiya ta Duniya a ranar Laraba, don tattauna ƙa'idodin ƙaddamar da bayanan ƙarshe da takaddun da ake buƙata.
Indiya ta fara yawan allurar rigakafin COVID-19 a ranar 16 ga Janairu ta hanyar ba da alluran rigakafin da aka yi a Indiya, wato Covishield da Covaxin.
Cibiyar Serum ta Indiya (SII) tana kera Covichield na Jami'ar AstraZeneca-Oxford, yayin da Bharat Biotech ya haɗu tare da Majalisar Indiya ta Binciken Likita (ICMR) a cikin masana'antar Covaxin.
An kuma kaddamar da rigakafin Sputnik V da Rasha ta yi a cikin kasar.Enditem
Lokacin aikawa: Juni-25-2021